A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study To Evaluate The Efficacy And Safety Of Sa237 As Monotherapy In Patients Wit
Posted Date: May 15, 2019
- Investigator: Aram Zabeti
- Type of Study: Drug
Neuromyelitis optica (NMO) and NMO spectrum disorder (NMOSD) are disorders of the immune system which cause damage to nerve coverings. The purpose of this research study is to find out if SA237 is safe and effective in patients with NMO or NMOSD. SA237 is an experimental drug which is not approved
Criteria:
You Are Being Asked To Take Part In This Research Study Because You Are 18 To 74 Years Of Age And Yo
Keywords:
Neuromyelitis Optica, Multiple Sclerosis, Nmo, Neuromyelitis Optica, Nmosd
For More Information:
Katie Krier
513-558-0169
krierci@ucmail.uc.edu